Your Navigation:PCAR > Abstract
Search pcar
Pharmaceutical Care and Research: 2017; 17(5):321-325
DOI: 10.5428/pcar20170501
Advances in new biomarkers of drug-induced liver injury
1. SHAO Zhen(Center of Drug Safety Evaluation and Research,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China
2. DENG ZhongPing(Center of Drug Safety Evaluation and Research,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China
ABSTRACT  As the focus of new drug research and development,drug-induced liver injury (DILI) is the difficulty of preclinical safety evaluation and clinical research,and also a hotspot in the study of liver diseases both at home and abroad in recent years. Due to the sensitivity,specificity and other factors,traditional indicators of DILI have limitations in the application of early evaluation. So discovery and verification of new biomarkers of DILI have become the focus of attention in new drug study and clinical diagnosis in recent years. In this paper,the status and prospects of new biomarkers of DILI were reviewed from the aspects of serum biology,cytokines,genomics,transcriptomics and metabolomics in order to provide reference for the prediction and diagnosis of DILI,and drug safety as well.
Welcome to PCAR! You are the number 147 reader of this article!
Please cite this article as:
SHAO Zhen,DENG ZhongPing,. Advances in new biomarkers of drug-induced liver injury[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2017; 17(5): 321-325.
1. Bjrnsson E S,Bergmann O M,Bjrnsson H K,et al.Incidence,presentation,and outcomes in patients with drug-induced liver injury in the general population of Iceland[J].Gastroenterology,2013,144(7):1419-1425.
2. Shin J,Hunt C M,Suzuki A,et al.Characterizing phenotypes and outcomes of drug-associated liver injury using electronic medical record data[J].Pharmacoepidemiol Drug Saf,2013,22(2):190-198.
3. WANG DanPing,YANG SuFen.Advances in biomarkers of drug-induced liver injury[J].Strait Pharm J,2014,26(6):13-16.In Chinese.
4. Li M,Li C,Allen A,et al.Glutamate dehydrogenase:structure,allosteric regulation,and role in insulin homeostasis[J].Neurochem Res,2014,39(3):433-445.
5. McGill M R,Sharpe M R,Williams C D,et al.The mechanism underlying acetaminophen-induced hepatotoxicity in humans and mice involves mitochondrial damage and nuclear DNA fragmentation[J].J Clin Invest,2012,122(4):1574-1583.
6. McGill M R,Williams C D,Xie Y,et al. Acetaminophen-induced liver injury in rats and mice:comparison of protein adducts, mitochondrial dysfunction,and oxidative stress in the mechanism of toxicity[J]. Toxicol Appl Pharmacol,2012,264(3):387-394.
7. Harrill A H,Roach J,Fier I,et al.The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers[J].Clin Pharmacol Ther,2012,92(2):214-220.
8. Schomaker S,Warner R,Bock J,et al.Assessment of emerging biomarkers of liver injury in human subjects[J].Toxicol Sci,2013,132(2):276-283.
9. Ferré N,Marsillach J,Camps J,et al. Paraoxonase-1 is associated with oxidative stress,fibrosis and FAS expression in chronic liver diseases[J].J Hepatol,2006,45(1):51-59.
10. LIU XiaoNa,PENG ShuangQing,JIA Li,et al.The changes of serum malic acid dehydrogenase and purine nucleoside phosphorylase in the early mice liver injury induced by acetaminophen[J].J Toxicol,2015,29(1):54-56.In Chinese.
11. Steuerwald N M,Foureau D M,Norton H J,et al.Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance[J].PLoS One,2013,8(12):e81974.
12. Fortier A M,Riopel K,Désaulniers M,et al.Novel insights into changes in biochemical properties of keratins 8 and 18 in griseofulvin-induced toxic liver injury[J].Exp Mol Pathol,2010,89(2):117-125.
13. SHI Ying,LI Juan,LIANG LianChun,et al.Expression of K18,Ser-33 and Ser-52 phosphorylated K18 in HBV infected human liver disease and its significance[J].Chin J Exp Clin Virol,2007,21(3):220-222.In Chinese with English abstract.
14. CHANG Yuan,WANG ShanShan,OUYANG YaBo,et al.The expression of keratin 18 and its Ser33 and Ser52 phosphorylation level changes in liver fibrosis in mice[J].Beijing Med J,2015,37(12):1171-1173.In Chinese with English abstract.
15. Snider N T,Weerasinghe S V,Iiguez-Lluhí J A,et al.Keratin hypersumoylation alters filament dynamics and is a marker for human liver disease and keratin mutation[J].J Biol Chem,2011,286(3):2273-2284.
16. Patel V B,Preedy V R.Biomarkers in liver disease[EB/OL].[2017-05-20].
17. Craig D G,Lee P,Pryde E A,et al.Elevated levels of the long pentraxin 3 in paracetamol-induced human acute liver injury[J].Eur J Gastroenterol Hepatol,2013,25(3):359-367.
18. Yaman H,Cakir E,Akgul E O,et al.Pentraxin 3 as a potential biomarker of acetaminophen-induced liver injury[J].Exp Toxicol Pathol,2013,65(1-2):147-151.
19. Yang H,Lundbck P,Ottosson L,et al.Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1)[J].Mol Med,2012,18(2):250-259.
20. Woolbright B L,Antoine D J,Jenkins R E,et al.Plasma biomarkers of liver injury and inflammation demonstrate a lack of apoptosis during obstructive cholestasis in mice[J].Toxicol Appl Pharmacol,2013,273(3): 524-531.
21. TIAN XueMei,MA TianTian,WANG YanE,et al. Research progress of the correlation between HLA gene polymorphism and serious adverse drug reactions[J]. Chin J New Drugs Clin Remed,2016,35(7):458-463.In Chinese with English abstract.
22. Dara L,Liu Z X,Kaplowitz N.Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury,clinical implications[J].Liver Int,2016,36(2):158-165.
23. Phillips E,Bartlett J A,Sanne I,et al.Associations between HLA-DRB1*0102,HLA-B*5801,and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa[J].J Acquir Immune Defic Syndr,2013,62(2):e55-e57.
24. SHI YanHui,JI ManRu,FU ZhongZe,et al.Study on the relationship between HLA gene polymorphism and susceptibility to liver cancer of population of Qiqihar[J].J Qiqihar Univ Med,2016,37(27):3437-3438.In Chinese.
25. Kim S H,Saide K,Farrell J,et al.Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury[J].Hepatology,2015,62(3):887-899.
26. Kaplowitz N.Avoiding idiosyncratic DILI: two is better than one[J].Hepatology,2013,58(1):15-17.
27. WANG YuPing,CHEN Tao,TONG WeiDa.miRNAs and their application in drug-induced liver injury[J].Biomarkers Med,2014,8(2):161-172.
28. WANG Yan,TANG NaPing,MA Jing.Progress in circulating miR-122 as potential biomarker for drug-induced liver injury[J].Chin J Pharmacol Toxicol,2013,27(1):110-113.In Chinese with English abstract.
29. Wolenski F S,Shah P,Sano T,et al.Identification of microRNA biomarker candidates in urine and plasma from rats with kidney or liver damage[J].J Appl Toxicol,2017,37(3):278-286.
30. Lyoumi S,Lefebvre T,Karim Z,et al.PXR-ALAS1:a key regulatory pathway in liver toxicity induced by isoniazid-rifampicin antituberculosis treatment[J].Clin Res Hepatol Gastroenterol,2013,37(5):439-441.
31. MA Lei,CHEN Huan,XU WanTing,et al.Role of heme oxygenase-1 in liver oxidative stress injury induced by rifampicin[J].J Chongqing Med Univ,2016,41(6):587-592.In Chinese with English abstract.
32. GAO Yuan,CAO ZhiJun,YANG Xi,et al.Proteomic analysis of acetaminophen-induced hepatotoxicity and identification of hemeoxygenase 1 as a potential plasma biomarker of liver injury[J]. Proteomics Clin Appl,2017,11(1-2).
33. Trottier J,Bialek A,Caron P,et al.Metabolomic profiling of 17 bile acids in serum from patients with primary biliary cirrhosis and primary sclerosing cholangitis: a pilot study[J].Dig Liver Dis,2012,44(4):303-310.
34. Luo L,Schomaker S,Houle C,et al.Evaluation of serum bile acid profiles as biomarkers of liver injury in rodents[J].Toxicol Sci,2014,137(1):12-25.
35. Yamazaki M,Miyake M,Sato H,et al.Perturbation of bile acid homeostasis is an early pathogenesis event of drug-induced liver injury in rats[J].Toxicol Appl Pharmacol,2013,268(1):79-89.
36. Kaur G,Leslie E M,Tillman H,et al.Detection of ophthalmic acid in serum from acetaminophen-induced acute liver failure patients is more frequent in non-survivors[J].PloS one,2015,10(9):e0139299.
37. Geenen S,Michopoulos F,Kenna J G,et al.HPLC-MS/MS methods for the quantitative analysis of ophthalmic acid in rodent plasma and hepatic cell line culture medium[J].J Pharm Biomed Anal,2011,54(5):1128-1135.
38. REN ZhangQing,WANG JinHai,GUO XiaoYan,et al.A review analysis of Chinese literatures 2005-2014:clinical features of drug-induced liver injury[J].Chin J Pharmacoepidemiol,2016,25(5):284-289.In Chinese with English abstract.
39. Antoine D J,Dear J W,Lewis P S,et al.Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital[J].Hepatology,2013,58(2): 777-787.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330